Lipid-Lowering Therapy

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 1087-1099

  Young, Ian S ^a   Loughrey, Brona V ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958754442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50091-X     Document Type: Chapter

References (49)

1. D Kromhout (2001) Epidemiology of cardiovascular diseases in Europe. Public Health Nutr 4(2B), 441-457.
2. RJ Goldberg, CM Burchfiel, R Benfante, et al. (1995) Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men: 20-year findings from the Honolulu Heart Program. Arch Intern Med 155 686-694.
3. BJ Ansell, M Navab, KE Watson, et al. (2004) Anti-inflammatory properties of HDL. Rev Endocr Metab Disord 5 351-358.
4. MA Austin, JE Hokanson and KL Edwards (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am I Cardiol 81 7B-12B.
5. A Hamsten, A Silveira, S Boquist, et al. (2005) The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J Am Coll Cardiol 45 1013-1017.
6. AC Jansen, ES van Aalst-Cohen, MW Tanck, et al. (2005) Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vase Biol 25 1475-1481.
7. PO Kwiterovich Jr (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol 86 5L-10L.
8. Q Guo, R Avramoglu and K Adeli (2005) Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: Evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 54 689-697.
9. GJ de Grooth, AH Klerkx, ES Stroes, et al. (2004) A review of CETP and its relation to atherosclerosis. J Lipid Res 45 1967-1974.
10. U Julius (2003) Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 111 246-250.
11. CJ Packard, T Demant, JP Stewart, et al. (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41 305-318.
12. A von Eckardstein, M Hersberger and L Rohrer (2005) Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 8 147-152.
13. E Stroes (2005) Statins and LDL-cholesterol lowering: An overview. Curr Med Res Opin 21 S9-16.
14. CJ Vaughan and AM Gotto Jr (2004) Update on statins: 2003. Circulation 110 886-892.
15. JP Despres, I Lemieux and SJ Robins (2004) Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 64 2177-2198.
16. DH van Raalte, M Li, PH Pritchard and KM Wasan (2004) Peroxisome proliferator-activated receptor (PPAR)-alpha: A pharmacological target with a promising future. Pharm Res 21 1531-1538.
17. PL McCormack and GM Keating (2005) Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65 2719-2740.
18. M Garcia-Calvo, J Lisnock, et al. (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Nati Acad Sci USA 102 8132-8137.
19. T Kosoglou, P Statkevich, AO Johnson-Levonas, et al. (2005) Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44 467-494.
20. D Bhatnagar and PN Durrington (2003) Omega-3 fatty acids: Their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract 57 305-314.
21. J Plat and RP Mensink (2005) Plant stanol and sterol esters in the control of blood cholesterol levels: Mechanism and safety aspects. Am J Cardiol 96 15D-22D.
22. M Ast and WH Frishman (1990) Bile acid sequestrants. J Clin Pharmacol 30 99-106.
23. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. (2005) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(5), v1-52.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 2486-2497.
25. G De Backer, E Ambrosioni, K Borch-Johnsen, et al. (2004) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mai Coeur Vaiss 97 1019-1030.
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (1994) The Scandinavian Simvastatin Survival Study (4S). Lancet 344 1383-1389.
27. J Shepherd, SM Cobbe, I Ford, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N EnglI Med 333 1301-1307.
28. MA Pfeffer, FM Sacks, LA Moye, et al. (1995) Cholesterol and Recurrent Events: A secondary prevention trial for normolipidemic patients. Am I Cardiol 76 98C-106C.
29. PS Sever, B Dahlof, NR Poulter, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial, Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 361 1149-1158.
30. HM Colhoun, DJ Betteridge, PN Durrington, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 685-696.
31. CP Cannon, E Braunwald, CH McCabe, et al. (2004) Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl I Med 350 1495-1504.
32. TR Pedersen, O Faergeman, JJ Kastelein, et al. (2005) Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial. JAMA 294 2437-2445. JAMA 294 3092. Erratum in
33. JC LaRosa, SM Grundy, DD Waters, et al. (2005) Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 1425-1435.
34. C Baigent, A Keech, PM Kearney, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 1267-1278. Lancet 366 1358. Erratum in
35. RW Nesto (2005) Beyond low-density lipoprotein: Addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am] Cardiovasc Drugs 5 379-387.
36. SJ Robins, D Collins, JT Wittes, et al. (2001) Veterans Affairs High-Density Lipoprotein Intervention Trial: Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. JAMA 285 1585-1591.
37. A Keech, RJ Simes, P Barter, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366 1849-1861.
38. PL Canner, KG Berge, NK Wenger, et al. (1986) Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 8 1245-1255.
39. PM Kris-Etherton, WS Harris and LJ Appel AHA Nutrition Committee (2003) Omega-3 fatty acids and cardiovascular disease: New recommendations from the American Heart Association. Arterioscler Thromb Vase Biol 23 151-152.
40. DJ Jenkins, CW Kendall, A Marchie, et al. (2005) Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr 81 380-387.
41. MR Law, SG Thompson and NJ Wald (1994) Assessing possible hazards of reducing serum cholesterol. BMJ 308 373-379.
42. AR Vasudevan, YS Hamirani and PH Jones (2005) Safety of statins: Effects on muscle and the liver. Cleve Clin J Med 72 990-993. 996–1001
43. Heart Protection Study Collaborative Group. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 7-22.
44. CB Newman, G Palmer, H Silbershatz and M Szarek (2003) Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92 670-676.
45. M Elisaf (2002) Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18 269-276.
46. TA Jacobson and FH Zimmerman (2006) Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 8 35-41.
47. J Shepherd, J Betteridge and L Van Gaal (2005) European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: A position paper developed by a European Consensus Panel. Curr Med Res Opin 21 665-682.
48. PJ Scheel Jr, A Whelton, K Rossiter and A Watson (1992) Cholestyramine-induced hyperchloremic metabolic acidosis. J Clin Pharmacol 32 536-538.
49. JS Forrester, R Makkar and PK Shah (2005) Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: An update for clinicians. Circulation 111 1847-1854.